1. Home
  2. GNS vs AYTU Comparison

GNS vs AYTU Comparison

Compare GNS & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genius Group Limited

GNS

Genius Group Limited

HOLD

Current Price

$0.14

Market Cap

32.1M

Sector

Real Estate

ML Signal

HOLD

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

SELL

Current Price

$2.05

Market Cap

27.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GNS
AYTU
Founded
2002
N/A
Country
Singapore
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.1M
27.4M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
GNS
AYTU
Price
$0.14
$2.05
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $9.50
AVG Volume (30 Days)
★ 5.0M
47.5K
Earning Date
09-28-2026
11-12-2026
Dividend Yield
★ 136.33%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $27,632,080.00
Revenue This Year
$127.02
$17.96
Revenue Next Year
$36.19
$27.98
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 277.47
52 Week Low
$0.14
$1.80
52 Week High
$1.06
$3.07

Technical Indicators

Market Signals
Indicator
GNS
AYTU
Relative Strength Index (RSI) 41.69 41.58
Support Level N/A $2.05
Resistance Level $0.23 $2.34
Average True Range (ATR) 0.01 0.11
MACD -0.00 -0.01
Stochastic Oscillator 15.94 13.16

Price Performance

Historical Comparison
GNS
AYTU

About GNS Genius Group Limited

Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: